143 related articles for article (PubMed ID: 18615538)
1. No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk.
Fall K; Stark JR; Mucci LA; Chan J; Stampfer MJ; Kurth T; Febbo PG; Kantoff P; Ma J
Prostate; 2008 Sep; 68(13):1416-20. PubMed ID: 18615538
[TBL] [Abstract][Full Text] [Related]
2. Circulating Insulin-Like Growth Factor 1-Related Biomarkers and Risk of Lethal Prostate Cancer.
Ma C; Wang Y; Wilson KM; Mucci LA; Stampfer MJ; Pollak M; Penney KL
JNCI Cancer Spectr; 2022 Feb; 6(1):. PubMed ID: 35047751
[TBL] [Abstract][Full Text] [Related]
3. Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer.
Koutros S; Schumacher FR; Hayes RB; Ma J; Huang WY; Albanes D; Canzian F; Chanock SJ; Crawford ED; Diver WR; Feigelson HS; Giovanucci E; Haiman CA; Henderson BE; Hunter DJ; Kaaks R; Kolonel LN; Kraft P; Le Marchand L; Riboli E; Siddiq A; Stampfer MJ; Stram DO; Thomas G; Travis RC; Thun MJ; Yeager M; Berndt SI
Cancer Res; 2010 Mar; 70(6):2389-96. PubMed ID: 20197460
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study.
Mucci LA; Stark JR; Pollak MN; Li H; Kurth T; Stampfer MJ; Ma J
Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):484-91. PubMed ID: 20142246
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.
Chan JM; Stampfer MJ; Ma J; Gann P; Gaziano JM; Pollak M; Giovannucci E
J Natl Cancer Inst; 2002 Jul; 94(14):1099-106. PubMed ID: 12122101
[TBL] [Abstract][Full Text] [Related]
6. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.
Stattin P; Bylund A; Rinaldi S; Biessy C; Déchaud H; Stenman UH; Egevad L; Riboli E; Hallmans G; Kaaks R
J Natl Cancer Inst; 2000 Dec; 92(23):1910-7. PubMed ID: 11106682
[TBL] [Abstract][Full Text] [Related]
7. Associations among IRS1, IRS2, IGF1, and IGFBP3 genetic polymorphisms and colorectal cancer.
Slattery ML; Samowitz W; Curtin K; Ma KN; Hoffman M; Caan B; Neuhausen S
Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1206-14. PubMed ID: 15247132
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor.
Chen C; Freeman R; Voigt LF; Fitzpatrick A; Plymate SR; Weiss NS
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2461-6. PubMed ID: 17164371
[TBL] [Abstract][Full Text] [Related]
9. Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2.
Ibrahim YH; Byron SA; Cui X; Lee AV; Yee D
Mol Cancer Res; 2008 Sep; 6(9):1491-8. PubMed ID: 18819936
[TBL] [Abstract][Full Text] [Related]
10. Insulin receptor substrate (IRS) proteins IRS-1 and IRS-2 differential signaling in the insulin/insulin-like growth factor-I pathways in fetal brown adipocytes.
Valverde AM; Lorenzo M; Pons S; White MF; Benito M
Mol Endocrinol; 1998 May; 12(5):688-97. PubMed ID: 9605931
[TBL] [Abstract][Full Text] [Related]
11. Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3.
Safarinejad MR; Shafiei N; Safarinejad S
Growth Horm IGF Res; 2011 Jun; 21(3):146-54. PubMed ID: 21536469
[TBL] [Abstract][Full Text] [Related]
12. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3).
Patel AV; Cheng I; Canzian F; Le Marchand L; Thun MJ; Berg CD; Buring J; Calle EE; Chanock S; Clavel-Chapelon F; Cox DG; Dorronsoro M; Dossus L; Haiman CA; Hankinson SE; Henderson BE; Hoover R; Hunter DJ; Kaaks R; Kolonel LN; Kraft P; Linseisen J; Lund E; Manjer J; McCarty C; Peeters PH; Pike MC; Pollak M; Riboli E; Stram DO; Tjonneland A; Travis RC; Trichopoulos D; Tumino R; Yeager M; Ziegler RG; Feigelson HS;
PLoS One; 2008 Jul; 3(7):e2578. PubMed ID: 18596909
[TBL] [Abstract][Full Text] [Related]
13. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
Woodson K; Tangrea JA; Pollak M; Copeland TD; Taylor PR; Virtamo J; Albanes D
Cancer Res; 2003 Jul; 63(14):3991-4. PubMed ID: 12873996
[TBL] [Abstract][Full Text] [Related]
14. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
Knowlden JM; Jones HE; Barrow D; Gee JM; Nicholson RI; Hutcheson IR
Breast Cancer Res Treat; 2008 Sep; 111(1):79-91. PubMed ID: 17902048
[TBL] [Abstract][Full Text] [Related]
15. Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial.
Miles FL; Goodman PJ; Tangen C; Torkko KC; Schenk JM; Song X; Pollak M; Thompson IM; Neuhouser ML
Nutrients; 2017 Apr; 9(4):. PubMed ID: 28417914
[TBL] [Abstract][Full Text] [Related]
16. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States).
Li L; Yu H; Schumacher F; Casey G; Witte JS
Cancer Causes Control; 2003 Oct; 14(8):721-6. PubMed ID: 14674736
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780.
Chan TW; Pollak M; Huynh H
Clin Cancer Res; 2001 Aug; 7(8):2545-54. PubMed ID: 11489838
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-1 (IGF-1) receptor-insulin receptor substrate complexes in the uterus. Altered signaling response to estradiol in the IGF-1(m/m) mouse.
Richards RG; Walker MP; Sebastian J; DiAugustine RP
J Biol Chem; 1998 May; 273(19):11962-9. PubMed ID: 9565625
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival.
Cao Y; Lindström S; Schumacher F; Stevens VL; Albanes D; Berndt S; Boeing H; Bueno-de-Mesquita HB; Canzian F; Chamosa S; Chanock SJ; Diver WR; Gapstur SM; Gaziano JM; Giovannucci EL; Haiman CA; Henderson B; Johansson M; Le Marchand L; Palli D; Rosner B; Siddiq A; Stampfer M; Stram DO; Tamimi R; Travis RC; Trichopoulos D; Willett WC; Yeager M; Kraft P; Hsing AW; Pollak M; Lin X; Ma J
J Natl Cancer Inst; 2014 Jun; 106(6):dju085. PubMed ID: 24824313
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
Guix M; Faber AC; Wang SE; Olivares MG; Song Y; Qu S; Rinehart C; Seidel B; Yee D; Arteaga CL; Engelman JA
J Clin Invest; 2008 Jul; 118(7):2609-19. PubMed ID: 18568074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
